Based on the Henry Schein Inc stock forecast from 7 analysts, the average analyst target price for Henry Schein Inc is USD 79.64 over the next 12 months. Henry Schein Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Henry Schein Inc is Slightly Bullish , which is based on 7 positive signals and 5 negative signals. At the last closing, Henry Schein Inc’s stock price was USD 66.54. Henry Schein Inc’s stock price has changed by -4.16% over the past week, -6.29% over the past month and -3.43% over the last year.
No recent analyst target price found for Henry Schein Inc
No recent average analyst rating found for Henry Schein Inc
Company Overview Henry Schein Inc
Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products, such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners; and value-added practice solutions comprising practice consultancy, education, revenue cycle management and financial services, e-services, practice technology, and network and hardware services, as well as consulting, and continuing education services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York. Read Less
Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, H...Read More
Frequently Asked Questions About Henry Schein Inc (HSIC) Stock
Based on ratings from 7 analysts Henry Schein Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 9 buy, sell and 5 hold ratings.
Unfortunately we do not have enough data on HSIC's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for HSIC is USD 79.64 over the next 12 months. The maximum analyst target price is USD 92 while the minimum anlayst target price is USD 70.
HSIC stock's Price/Earning ratio is 25.97.
Our analysis grades HSIC stock's Price / Earning ratio at D+. This means that HSIC stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Medical Distribution sector in the NSD exchange.
Based on this HSIC may be fairly valued for its sector
The last closing price of HSIC's stock was USD 66.54.
The most recent market capitalization for HSIC is USD 8.92B.
Based on targets from 7 analysts, the average taret price for HSIC is projected at USD 79.64 over the next 12 months.
This means that HSIC's stock price may go up by +19.69% over the next 12 months.
We can't find any ETFs which contains Henry Schein Inc's stock.
As per our most recent records Henry Schein Inc has 26,000 Employees.
Henry Schein Inc's registered address is 135 Duryea Road, Melville, NY, United States, 11747.
You can get more information about it from Henry Schein Inc's website at https://www.henryschein.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Henry Schein Inc (HSIC) Stock
Based on ratings from 7 analysts Henry Schein Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 9 buy, sell and 5 hold ratings.
Unfortunately we do not have enough data on HSIC's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for HSIC is USD 79.64 over the next 12 months. The maximum analyst target price is USD 92 while the minimum anlayst target price is USD 70.
HSIC stock's Price/Earning ratio is 25.97.
Our analysis grades HSIC stock's Price / Earning ratio at D+. This means that HSIC stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Medical Distribution sector in the NSD exchange.
Based on this HSIC may be fairly valued for its sector
The last closing price of HSIC's stock was USD 66.54.
The most recent market capitalization for HSIC is USD 8.92B.
Based on targets from 7 analysts, the average taret price for HSIC is projected at USD 79.64 over the next 12 months.
This means that HSIC's stock price may go up by +19.69% over the next 12 months.
We can't find any ETFs which contains Henry Schein Inc's stock.
As per our most recent records Henry Schein Inc has 26,000 Employees.
Henry Schein Inc's registered address is 135 Duryea Road, Melville, NY, United States, 11747.
You can get more information about it from Henry Schein Inc's website at https://www.henryschein.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for HSIC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
